FindTrial
Sign In

MRD reappearance predicted the disease progression in patients with multiple myeloma

MRD reappearance predicted the disease progression in patients with multiple myeloma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044792
Enrollment
Unknown
Registered
2021-03-27
Start date
2020-06-01
Completion date
Unknown
Last updated
2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

case series:Nil

Sponsors

The First Affiliated Hospital of Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed multiple myeloma diagnosed according to IMWG 2016 criteria; 2. Patients had received bortezomib based regimen induction and subsequent ASCT plus continuous maintenance; 3. Patients had received regular sequential MRD monitoring; 4. Patients had achieved MRD negativity after transplantation; 5. Patients had MRD reappearance after achieving the MRD negativity.

Exclusion criteria

Exclusion criteria: Patients received preemptive therapy before disease progression.

Design outcomes

Primary

MeasureTime frame
Time from MRD reappearance to PD;—

Countries

China

Contacts

Public ContactLi Juan

The First Affiliated Hospital of Sun Yat-Sen University

ljuan@mail.sysu.edu.cn+86 13719209240

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026